Switch theme
Sign up to access all valuation multiples
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
2004
21.4K+
LTM Revenue $1.8B
LTM EBITDA $434M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharmaron Beijing has a last 12-month revenue (LTM) of $1.8B and a last 12-month EBITDA of $434M.
In the most recent fiscal year, Pharmaron Beijing achieved revenue of $1.7B and an EBITDA of $470M.
Pharmaron Beijing expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharmaron Beijing valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Profit | $618M | XXX | $583M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $434M | XXX | $470M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $277M | XXX | $259M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $248M | XXX | $249M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $479M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pharmaron Beijing's stock price is CNY 22 (or $3).
Pharmaron Beijing has current market cap of CNY 39.4B (or $5.5B), and EV of CNY 42.7B (or $5.9B).
See Pharmaron Beijing trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $5.5B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pharmaron Beijing has market cap of $5.5B and EV of $5.9B.
Pharmaron Beijing's trades at 3.5x EV/Revenue multiple, and 12.6x EV/EBITDA.
Equity research analysts estimate Pharmaron Beijing's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharmaron Beijing has a P/E ratio of 22.1x.
See valuation multiples for Pharmaron Beijing and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.5B | XXX | $5.5B | XXX | XXX | XXX |
| EV (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.7x | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBIT | 21.4x | XXX | 22.9x | XXX | XXX | XXX |
| EV/Gross Profit | 9.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.1x | XXX | 22.0x | XXX | XXX | XXX |
| EV/FCF | 54.0x | XXX | 79.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmaron Beijing's last 12 month revenue growth is 13%
Pharmaron Beijing's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $15K for the same period.
Pharmaron Beijing's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharmaron Beijing's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharmaron Beijing and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $15K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharmaron Beijing acquired XXX companies to date.
Last acquisition by Pharmaron Beijing was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharmaron Beijing acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pharmaron Beijing founded? | Pharmaron Beijing was founded in 2004. |
| Where is Pharmaron Beijing headquartered? | Pharmaron Beijing is headquartered in China. |
| How many employees does Pharmaron Beijing have? | As of today, Pharmaron Beijing has 21.4K+ employees. |
| Who is the CEO of Pharmaron Beijing? | Pharmaron Beijing's CEO is Dr. Boliang Lou. |
| Is Pharmaron Beijing publicy listed? | Yes, Pharmaron Beijing is a public company listed on SHE. |
| What is the stock symbol of Pharmaron Beijing? | Pharmaron Beijing trades under 300759 ticker. |
| When did Pharmaron Beijing go public? | Pharmaron Beijing went public in 2019. |
| Who are competitors of Pharmaron Beijing? | Similar companies to Pharmaron Beijing include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Pharmaron Beijing? | Pharmaron Beijing's current market cap is $5.5B |
| What is the current revenue of Pharmaron Beijing? | Pharmaron Beijing's last 12 months revenue is $1.8B. |
| What is the current revenue growth of Pharmaron Beijing? | Pharmaron Beijing revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Pharmaron Beijing? | Current revenue multiple of Pharmaron Beijing is 3.3x. |
| Is Pharmaron Beijing profitable? | Yes, Pharmaron Beijing is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharmaron Beijing? | Pharmaron Beijing's last 12 months EBITDA is $434M. |
| What is Pharmaron Beijing's EBITDA margin? | Pharmaron Beijing's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Pharmaron Beijing? | Current EBITDA multiple of Pharmaron Beijing is 13.7x. |
| What is the current FCF of Pharmaron Beijing? | Pharmaron Beijing's last 12 months FCF is $110M. |
| What is Pharmaron Beijing's FCF margin? | Pharmaron Beijing's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Pharmaron Beijing? | Current FCF multiple of Pharmaron Beijing is 54.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
